These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30667283)

  • 1. Systemic Inflammation and Cardio-Renal Organ Damage Biomarkers in Middle Age Are Associated With Physical Capability Up to 9 Years Later.
    Kuh D; Cooper R; Sattar N; Welsh P; Hardy R; Ben-Shlomo Y
    Circulation; 2019 Apr; 139(17):1988-1999. PubMed ID: 30667283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in N-terminal pro-brain natriuretic peptide levels, renal function and cardiac disease in the oldest old.
    Poortvliet R; de Craen A; Gussekloo J; de Ruijter W
    Age Ageing; 2015 Sep; 44(5):841-7. PubMed ID: 26209786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory markers and incident heart failure in older men: the role of NT-proBNP.
    McKechnie DG; Papacosta AO; Lennon LT; Welsh P; Whincup PH; Wannamethee SG
    Biomark Med; 2021 Apr; 15(6):413-425. PubMed ID: 33709785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
    Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Socioeconomic position is associated with N-terminal pro-brain natriuretic peptide (NT-proBNP)-Results of the population-based Heinz Nixdorf Recall study.
    Rudman M; Frank M; Emmel C; Matusch E; Kara K; Mahabadi AA; Erbel R; Jöckel KH; Dragano N; Schmidt B
    PLoS One; 2021; 16(8):e0255786. PubMed ID: 34415953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure.
    Skoglund PH; Arpegård J; Ostergren J; Svensson P
    Am J Hypertens; 2014 Mar; 27(3):363-71. PubMed ID: 24470529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD.
    Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M
    Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249
    [No Abstract]   [Full Text] [Related]  

  • 8. Cystatin C, NT-proBNP, and inflammatory markers in acute heart failure: insights into the cardiorenal syndrome.
    Lassus JP; Harjola VP; Peuhkurinen K; Sund R; Mebazaa A; Siirilä-Waris K; Miettinen K; Punnonen KR; Melin J; Pulkki K; Nieminen MS;
    Biomarkers; 2011 Jun; 16(4):302-10. PubMed ID: 21417622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism.
    Folsom AR; Lutsey PL; Heckbert SR; Poudel K; Basu S; Hoogeveen RC; Cushman M; Ballantyne CM
    J Thromb Haemost; 2018 Oct; 16(10):1964-1972. PubMed ID: 30007116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study.
    Truong QA; Szymonifka J; Januzzi JL; Contractor JH; Deaño RC; Chatterjee NA; Singh JP
    Heart Rhythm; 2019 Jun; 16(6):928-935. PubMed ID: 30590191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical activity in older men: longitudinal associations with inflammatory and hemostatic biomarkers, N-terminal pro-brain natriuretic peptide, and onset of coronary heart disease and mortality.
    Jefferis BJ; Whincup PH; Lennon LT; Papacosta O; Goya Wannamethee S
    J Am Geriatr Soc; 2014 Apr; 62(4):599-606. PubMed ID: 24635212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natriuretic and Inflammatory Biomarkers as Risk Predictors of Heart Failure in Middle-Aged Men From the General Population: A 21-Year Follow-Up.
    Ergatoudes C; Thunström E; Hansson PO; Morales D; Mandalenakis Z; Rosengren A; Zhong Y; Caidahl K; Fu M
    J Card Fail; 2018 Sep; 24(9):594-600. PubMed ID: 30048772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin Resistance and N-Terminal Pro-B-Type Natriuretic Peptide Among Healthy Adults.
    Echouffo-Tcheugui JB; Zhang S; McEvoy JW; Juraschek SP; Fang M; Ndumele CE; Christenson RH; Selvin E
    JAMA Cardiol; 2023 Oct; 8(10):989-995. PubMed ID: 37672260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.
    Flores-Blanco PJ; Manzano-Fernández S; Pérez-Calvo JI; Pastor-Pérez FJ; Ruiz-Ruiz FJ; Carrasco-Sánchez FJ; Morales-Rull JL; Pascual-Figal D; Galisteo-Almeda L; Januzzi JL
    Clin Cardiol; 2015 Feb; 38(2):106-13. PubMed ID: 25663560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Levels of Cystatin C, N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP), and Cardiac Function in Patients with Unstable Angina Pectoris.
    Long M; Li L
    Med Sci Monit; 2020 Mar; 26():e920721. PubMed ID: 32165608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.
    Natriuretic Peptides Studies Collaboration ; Willeit P; Kaptoge S; Welsh P; Butterworth AS; Chowdhury R; Spackman SA; Pennells L; Gao P; Burgess S; Freitag DF; Sweeting M; Wood AM; Cook NR; Judd S; Trompet S; Nambi V; Olsen MH; Everett BM; Kee F; Ärnlöv J; Salomaa V; Levy D; Kauhanen J; Laukkanen JA; Kavousi M; Ninomiya T; Casas JP; Daniels LB; Lind L; Kistorp CN; Rosenberg J; Mueller T; Rubattu S; Panagiotakos DB; Franco OH; de Lemos JA; Luchner A; Kizer JR; Kiechl S; Salonen JT; Goya Wannamethee S; de Boer RA; Nordestgaard BG; Andersson J; Jørgensen T; Melander O; Ballantyne ChM; DeFilippi Ch; Ridker PM; Cushman M; Rosamond WD; Thompson SG; Gudnason V; Sattar N; Danesh J; Di Angelantonio E
    Lancet Diabetes Endocrinol; 2016 Oct; 4(10):840-9. PubMed ID: 27599814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach.
    Svennberg E; Lindahl B; Berglund L; Eggers KM; Venge P; Zethelius B; Rosenqvist M; Lind L; Hijazi Z
    Int J Cardiol; 2016 Nov; 223():74-81. PubMed ID: 27541645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of N-terminal pro-B-type natriuretic peptide in determining antihypertensive benefit: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Welsh P; Poulter NR; Chang CL; Sever PS; Sattar N;
    Hypertension; 2014 Mar; 63(3):507-13. PubMed ID: 24324046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes.
    Bertoni AG; Wagenknecht LE; Kitzman DW; Marcovina SM; Rushing JT; Espeland MA;
    Obesity (Silver Spring); 2012 Jul; 20(7):1511-8. PubMed ID: 21959345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.